Skip to main navigation
Skip to main content
Denali Therapeutics
  • Home
  • Scientific Approach
    • GENETIC PATHWAY POTENTIAL
    • ENGINEERING BRAIN DELIVERY
    • BIOMARKER-DRIVEN DEVELOPMENT
    • PUBLICATIONS
  • Pipeline
  • Patients
  • Investor & Media Relations
    • Press Releases
    • Events
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
  • Leadership
  • Partnering
  • Careers
    • Job Openings
    • STEM Outreach Overview
    • Student Internships
    • Postdoc Program
  • Contact

SEC Filings

Sign Up For Updates
Filing date Form Description View
Sep 08, 2017 DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy View HTML
0000950123-17-008432.pdf
0000950123-17-008432.rtf
0000950123-17-008432.xls
Pagination
  • First page «
  • Previous page ‹
  • …
  • Page 71
  • Page 72
  • Current page 73
Displaying 721 - 721 of 721 results

Sign up for email alerts

Stay in the loop with updates on the latest Denali news delivered right to your inbox


  • Investor & Media Relations

CONTACT US

161 Oyster Point Blvd- South San Francisco, CA 94080

© 2025 Denali Therapeutics

  • Privacy Policy
  • Terms of Use

©2025 Denali Therapeutics | 161 Oyster Point Boulevard, South San Francisco, CA 94080

  • Privacy Policy
  • Terms of Use